KSKatri S. Selander

Katri S. Selander

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katri S. Selander has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer

    by Johanna Tuomela, Jouko Sandholm, Peeter Karihtala, Joanna Ilvesaro, Katri S. Vuopala, Joonas H. Kauppila, Saila Kauppila, Dongquan Chen, Christine Pressey, Pirkko Härkönen, et al.

    Toll-like receptor-9 (TLR9) is a DNA receptor widely expressed in cancers. Although synthetic TLR9 ligands induce cancer cell invasion in vitro, the role of TLR9 in cancer pathophysiology is unclear. We discovered that low tumor TLR9 expression is associated with significantly shortened disease-specific survival in patients with triple negative but not with ER+ breast cancers. A likely mechanism of this clinical finding involves differential responses to hypoxia. Our pre-clinical studies indicate that while TLR9 expression is hypoxia-regulated, low TLR9 expression has different effects on triple negative and ER+ breast cancer invasion in hypoxia. Hypoxia-induced invasion is augmented by TLR9 siRNA in triple negative, but not in ER+ breast cancer cells. This is possibly due to differential TLR9-regulated TIMP-3 expression, which remains detectable in ER+ cells but disappears from triple-negative TLR9 siRNA cells in hypoxia. Our results demonstrate a novel role for this innate immunity receptor in cancer biology and suggest that TLR9 expression may be a novel marker for triple-negative breast cancer patients who are at a high risk of relapse. Furthermore, these results suggest that interventions or events, which induce hypoxia or down-regulate TLR9 expression in triple-negative breast cancer cells may actually induce their spread.


  • Open Access

    Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma

    by Hanna Ronkainen, Pasi Hirvikoski, Saila Kauppila, Katri S Vuopala, Timo K Paavonen, Katri S Selander, Markku H Vaarala

    Toll-like receptor 9 (TLR9) is a cellular DNA-receptor whose activation with cognate ligands triggers an immune reaction, with increased production of inflammatory cytokines. The aim of this study was to examine the expression of TLR9 in renal cell carcinoma (RCC), which is generally renowned of its immunogenic nature. We also evaluated the prognostic value of TLR9 in RCC.


  • Estrogen receptor-α and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells

    by Jouko Sandholm, Joonas H. Kauppila, Christine Pressey, Johanna Tuomela, Arja Jukkola-Vuorinen, Markku Vaarala, Martin R. Johnson, Kevin W. Harris, Katri S. Selander

    Toll-like receptor 9 (TLR9) is a cellular DNA-receptor, which is widely expressed in cancer. Synthetic TLR9-ligands induce cancer cell invasion in vitro, but the role of TLR9 in cancer pathophysiology remains unclear. Increased TLR9 expression has been, however, detected in estrogen receptor negative (ER−) breast cancers. In this study, we investigated the effects of ERα expression and sex steroid hormones on TLR9 expression in human ER+ (MCF-7, T47-D) and ER− (MDA-MB-231) breast cancer cell lines in vitro. We also studied TLR9 mRNA expression in archival breast cancer specimens (n = 12) with qRT-PCR, using primer sets that detect only the TLR9A isoform or the isoforms A and B (TLR9A/B). The TLR9 mRNA expression was detected in 10/12 specimens with both primer sets, and in 1/12 with only the TLR9A or the TLR9A/B primer sets. The basal TLR9 mRNA expression levels were significantly lower in the ER+ cell lines as compared with the ER− MDA-MB-231 cells. The transfection of ERα cDNA into MDA-MB-231 cells also resulted in down-regulation of TLR9 expression. While sex steroids had no effect on TLR9 expression in MCF-7 cells, testosterone (10−8 M) induced TLR9 expression in MDA-MB-231 and T47-D cells. Although bicalutamide blocked this testosterone effect in MDA-MB-231 cells, in T47-D cells bicalutamide increased TLR9 expression and only partially blocked the testosterone effects. Estradiol (10−8 M) induced TLR9 expression in T47-D cells. The invasive effects of synthetic TLR9-ligands were augmented by testosterone in vitro. This effect was lost in TLR9 siRNA MDA-MB-231 cells and also decreased by over-expression of ERα, which also inhibited NF-κB activation by TLR9-ligands. In conclusion, expression of TLR9 isoforms A and B can be detected in clinical breast cancer specimens. The ERα and sex steroid hormones regulate TLR9 expression and invasive effects in the breast cancer cells. Also, the commonly used hormonal cancer therapy bicalutamide affects TLR9 expression.


  • Expression of macrophage inhibitory cytokine‐1 in prostate cancer bone metastases induces osteoclast activation and weight loss

    by Savita Wakchoure, Telisha Millender Swain, Teuvo A. Hentunen, Asne R. Bauskin, David A. Brown, Samuel N. Breit, Katri S. Vuopala, Kevin W. Harris, Katri S. Selander

    BACKGROUND: Macrophage inhibitory cytokine‐1 (MIC‐1) belongs to the bone morphogenic protein/transforming growth factor‐β (BMP/TGF‐β) superfamily. Serum MIC‐1 concentrations are elevated in patients with advanced prostate cancer. The effects of MIC‐1 on prostate cancer bone metastases are unknown.METHODS: In vitro effects of MIC‐1 on osteoblast differentiation and activity were analyzed with alkaline phosphatase and mineralization assays; osteoclast numbers were counted microscopically. MIC‐1 effects on TLR9 expression were studied with Western blotting. Human Du‐145 prostate cancer cells were stably transfected with a cDNA encoding for mature MIC‐1 or with an empty vector. The in vivo growth characteristics of the characterized cells were studied with the intra‐tibial model of bone metastasis. Tumor associated bone changes were viewed with X‐rays, histology, and histomorphometry. Bone formation was assayed by measuring serum PINP.RESULTS: MIC‐1 induced osteoblast differentiation and activity and osteoclast formation in vitro. These effects were independent of TLR9 expression, which was promoted by MIC‐1. Both MIC‐1 and control tumors induced mixed sclerotic/lytic bone lesions, but MIC‐1 increased the osteolytic component of tumors. Osteoclast formation at the tumor–bone interface was significantly higher in the MIC‐1 tumors, whereas bone formation was significantly higher in the control mice. At sacrifice, the mice bearing MIC‐1 tumors were significantly lighter with significantly smaller tumors.CONCLUSIONS: MIC‐1 up‐regulates TLR9 expression in various cells. MIC‐1 stimulates both osteoblast and osteoclast differentiation in vitro, independently of TLR9. MIC‐1 over‐expressing prostate cancer cells that grow in bone induce osteoclast formation and cachexia. Prostate 69:652–661, 2009.


  • Open Access

    Toll-Like Receptor 9 Mediates CpG Oligonucleotide–Induced Cellular Invasion

    by Joanna M. Ilvesaro, Melinda A. Merrell, Li Li, Savita Wakchoure, David Graves, Sonja Brooks, Eeva Rahko, Arja Jukkola-Vuorinen, Katri S. Vuopala, Kevin W. Harris, et al.

    Toll-like receptor 9 (TLR9) belongs to the innate immune system and recognizes microbial and vertebrate DNA. We showed previously that treatment with the TLR9-agonistic ODN M362 (a CpG sequence containing oligonucleotide) induces matrix metalloproteinase-13–mediated invasion in TLR9-expressing human cancer cell lines. Here, we further characterized the role of the TLR9 pathway in this process. We show that CpG oligonucleotides induce invasion in macrophages from wild-type C57/B6 and MyD88 knockout mice and in human MDA-MB-231 breast cancer cells lacking MyD88 expression. This effect was significantly inhibited in macrophages from TLR9 knockout mice and in human MDA-MB-231 breast cancer cells stably expressing TLR9 small interfering RNA or dominant-negative tumor necrosis factor receptor-associated factor 6 (TRAF6). Sequence modifications to the CpG oligonucleotides that targeted the stem loop and other secondary structures were shown to influence the invasion-inducing effect in MDA-MB-231 cells. In contrast, methylation of the cytosine residues of the parent CpG oligonucleotide did not affect the TLR9-mediated invasion compared with the unmethylated parent CpG oligonucleotide. Finally, expression of TLR9 was studied in clinical breast cancer samples and normal breast epithelium with immunohistochemistry. TLR9 staining localized in epithelial cells in both cancer and normal samples. The mean TLR9 staining intensity was significantly increased in the breast cancer cells compared with normal breast epithelial cells. In conclusion, our results suggest that TLR9 expression is increased in breast cancer and CpG oligonucleotide–induced cellular invasion is mediated via TLR9 and TRAF6, independent of MyD88. Further, our findings suggest that the structure and/or stability of DNA may influence the induction of TLR9-mediated invasion in breast cancer. (Mol Cancer Res 2008;6(10):1534–43)


  • Open Access

    Toll-Like Receptor-9 Expression Is Inversely Correlated with Estrogen Receptor Status in Breast Cancer

    by Arja Jukkola-Vuorinen, Eeva Rahko, Katri S. Vuopala, Renee Desmond, Petri P. Lehenkari, Kevin W. Harris, Katri S. Selander

    Toll-like receptor 9 (TLR9) recognizes microbial and vertebrate DNA. We previously demonstrated TLR9 expression in human breast cancer cell lines and showed that TLR9 ligands stimulate their in vitro invasion. The aim of this study was to characterize TLR9 expression in clinical breast cancer specimens. Immunohistochemical staining intensity was compared with known baseline prognostic factors and distant metastasis-free survival. TLR9 expression was detected in 98% of the tumors studied (n = 141). The mean TLR9 staining intensity was higher in ER– than in the highly ER+ breast cancers (p = 0.039). High-grade tumors had significantly increased TLR9 expression (p = 0.027) compared with lower-grade tumors. The highest TLR9 expression was detected in the mucinous and the lowest in the tubular breast cancers (p = 0.034). Distant metastasis-free survival was higher in the lower TLR9-expressing half of the cohort than in the higher TLR9-expressing group (p = 0.118). TLR9 expression did not correlate with menopausal, PgR or Her2 status, patient age, tumor proliferative or invasive characteristics.


  • Toll like receptor‐9 agonists stimulate prostate cancer invasion in vitro

    by Joanna M. Ilvesaro, Melinda A. Merrell, Telisha Millender Swain, Jennifer Davidson, Majd Zayzafoon, Kevin W. Harris, Katri S. Selander

    BACKGROUND: Toll‐like receptor 9 (TLR9) recognizes microbial DNA. In addition to immune cells, TLR9 expression has been detected in various cancer cells. We showed recently that TLR9 agonistic CpG‐oligonucleotides (CpG‐ODNs) induce matrix metalloproteinase‐13 (MMP‐13)‐mediated invasion in TLR9‐expressing (TLR9+) breast cancer cells. We investigated here TLR9 expression and function in human prostate cancer (CaP) cells.METHODS: TLR9 expression was detected with Western blotting and immunohistochemistry. Invasion was studied with Matrigel‐assays. MMP‐13 was assayed with ELISA.RESULTS: Human CaP cell lines and clinical samples exhibit various levels of TLR9 expression. Treatment of TLR9+, but not TLR9− CaP cells with CpG‐ODNs or bacterial DNA increased their invasion, which was inhibited with chloroquine. CpG‐ODN‐treatment also increased MMP‐13 activity and neutralizing anti‐MMP‐13 antibody prevented CpG‐ODN‐induced invasion in TLR9+ CaP cells. Estradiol up‐regulated TLR9 expression in LnCaP cells.CONCLUSIONS: TLR9‐mediated invasion may represent a novel mechanism through which infections promote prostate cancer. Prostate 67: 774–781, 2007.


  • Serum Macrophage Inhibitory Cytokine-1 Concentrations Correlate with the Presence of Prostate Cancer Bone Metastases

    by Katri S. Selander, David A. Brown, Guillermo Blanco Sequeiros, Mark Hunter, Renee Desmond, Teija Parpala, Juha Risteli, Samuel N. Breit, Arja Jukkola-Vuorinen

    Macrophage-inhibitory cytokine-1 (MIC-1) is a divergent member of the transforming growth factor β superfamily. It is up-regulated by nonsteroidal anti-inflammatory drugs and is highly expressed in human prostate cancer leading to high serum MIC-1 concentrations with advanced disease. A role for MIC-1 has been implicated in the process of early bone formation, suggesting that it may also mediate sclerosis at the site of prostate cancer bone metastases. Consequently, the aim of this study was to retrospectively determine the relationship of serum MIC-1 concentration and other markers related to current and future prostate cancer bone metastasis in a cohort of 159 patients with prostate cancer. Serum markers included cross-linked carboxy-terminal telopeptide of type I collagen, prostate-specific antigen, and amino-terminal propeptide of type I procollagen (PINP). The mean values of all the biomarkers studied were significantly higher in patients with baseline bone metastases (BM+, n = 35), when compared with those without bone metastases (BM−, n = 124). In a multivariate logistic model, both MIC-1 and PINP independently predicted the presence of baseline bone metastasis. Based on receiver operator curve analysis, the best predictor for the presence of baseline bone metastasis was MIC-1, which was significantly better than carboxy-terminal telopeptide of type I collagen, prostate-specific antigen, and PINP. Patients who experienced bone relapse had significantly higher levels of baseline MIC-1 compared with patients who did not (1476.7 versus 988.4; P = 0.03). Current use of acetylsalicylic acid did not influence serum MIC-1 levels in this cohort. Although requiring validation prospectively, these results suggest that serum MIC-1 determination may be a valuable tool for the diagnosis of current and future bone metastases in patients with prostate cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(3):532–7)


  • Breast cancer cells with inhibition of p38<>α have decreased MMP-9 activity and exhibit decreased bone metastasis in mice

    by Catalina Suarez-Cuervo, Melinda A. Merrell, Latania Watson, Kevin W. Harris, Eben L. Rosenthal, H. Kalervo. Väänänen, Katri S. Selander

    P38 belongs to a family of mitogen-activated protein kinases, which transfer extracellular signals into intracellular responses. p38 is also frequently detected in clinical breast cancer specimens, but its role as a prognostic factor is not known. Of the various p38 isoforms, p38β has been shown to mediate the in vitro invasiveness of breast cancer cells through up-regulation of urokinase plasminogen activator (uPA). We studied the role of p38β in breast cancer bone metastases, using dominant negative blockade approach. Human MDA-MB-231 breast cancer clones stably expressing dominant negative p38β (p38/AF) exhibited decreased basal MMP-9 activity. TGF-β 1-induced MMP-9 activity was also blunted in these clones, as compared with controls in which TGF-β 1 up-regulated MMP-9 activity. Consistent with these findings, SB202190, a specific p38 inhibitor, also inhibited TGF-β1-induced MMP-9 activity in parental cells. The p38/AF clones exhibited also reduced uPA production after growth on vitronectin and decreased cell motility, as compared with controls. VEGF production levels in all the studied clones were similar. The p38/AF clone, which had similar in vitro growth rate as the control pcDNA3 clone, formed significantly less bone metastases in a mouse model, as compared with the control clone. In conclusion, inhibition of the p38β pathway results in decreased MMP-9 activity, impaired uPA expression and decreased motility, all of which may contribute to the decreased formation of bone metastasis.